Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclatasvir + PegIFN/RBV in HCV GT 1 and 4
NCT01797848Phase 3Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2014
- Primary completion
- Nov 2016
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of daclatasvir in hepatitis C (HCV), sponsored by Bristol Myers Squibb. Planned start Jun 2014; status: withdrawn.
02
Drugs
daclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01797848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01797848.